Word is getting out alright. That REGEN is a POS penny stock run by a very sleazy CEO who has already run two other companies into the ground. The same is happening here. The scientific community doesn't give 10 hemaxellerate rat asses about Regen. If FDA IND approval happens and the trial is successful in reversing aplastic anemia, then things will move but until then, the stock will suffer mostly due to the fact that it's an otc stock that the investment community won't be able to invest in.
News 
Market Data 
Discover 
AI
